Arthur D. Little Publishes Special 135th Anniversary Edition of PRISM Magazine
17.12.2021 17:11:00 EET | Business Wire | Press release
Arthur D. Little (ADL) has published Who Says It Can’t Be Done? – the latest edition of its innovation magazine PRISM. As well as celebrating the company’s 135-year history, this special edition looks ahead to both the future of business and the consulting industry itself.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005298/en/
Arthur D. Little Prism Magazine (Photo: Business Wire)
The magazine features five key articles:
- Rebalancing For Tomorrow – The ability to help clients anticipate the future, embrace new opportunities, and transform their operations has always been a central part of ADL’s consulting philosophy. This article looks at the challenges that business faces today, identifies important priorities for the future, and reflects on how companies can get ready to meet them.
- Why Consultancy Matters: A Historical Perspective – What is the exact nature of management consultancy’s value? Does consulting merely provide a similar service to that of the accountancy or legal professions, or does it provide a different type of value? This article explores how management consultancy has helped to shape the world we live in today as illustrated by the history of ADL.
- The Future Of Consultancy – In today’s volatile environment, companies are looking for more than just me-too solutions to remain competitive. The consulting industry needs to reconfigure its approach and reject obsolete legacy models if it is to stay relevant to modern business. This article looks at some of the ways in which consulting must change in order to create real value for its clients.
- Inventors, Innovators, Pathfinders – Since the days of Arthur Dehon Little himself, ADL has been driven by hugely talented individuals, all pathfinders in their own right. This article celebrates some of the extraordinary people who have both led ADL and pioneered its unique approach to consultancy, inventing new solutions and breaking down barriers along the way.
- Who Says It Can’t Be Done? – It was only after a management buyout (MBO) on 30 December 2011 that ADL was truly reborn as a successful partnership with a rapidly expanding business. In this interview with Ignacio Garcia-Alves, who led the MBO and has been ADL’s Chief Executive Officer ever since, he shares his insights on how the company was transformed and the lessons learned over the past ten years.
Ignacio García Alves, Global Chairman and Chief Executive Officer of Arthur D. Little, comments: “PRISM always offers the best in thought-leading insight and commentary on the key topics of the day, and this edition is no exception – but with ADL hitting the milestone of 135 years of constant innovation, we couldn’t resist also looking back on what’s made it such a unique and pioneering company.”
This latest edition of PRISM can be viewed here: https://tinyurl.com/9hyefpch
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211217005298/en/
Contact information
Further information from: Cate Bonthuys
Catalyst Comms
+44 7746 546773
cate@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
